Pharmacogenetics of ABCG2 and Adverse Reactions to Gefitinib-Reference-Cited by-同舟云学术

Pharmacogenetics of ABCG2 and Adverse Reactions to Gefitinib

Published:2006-12-06 Issue:23 Volume:98 Page:1739-1742
ISSN:1460-2105
Container-title:JNCI: Journal of the National Cancer Institute
language:en
Short-container-title:

Author:

Cusatis George,Gregorc Vanesa,Li Jing,Spreafico Anna,Ingersoll Roxann G.,Verweij Jaap,Ludovini Vienna,Villa Eugenio,Hidalgo Manuel,Sparreboom Alex,Baker Sharyn D.

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

http://academic.oup.com/jnci/article-pdf/98/23/1739/7688111/djj469.pdf

Reference26 articles.

1. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol2003 ; 21 : 2237 –46.

2. Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA2003 ; 290 : 2149 –58.

3. Mohamed MK, Ramalingam S, Lin Y, Gooding W, Belani CP. Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small cell lung cancer. Ann Oncol2005 ; 16 : 780 –5.

4. Razis E, Skarlos D, Briasoulis E, DimopoulosM, Fountzilas G, Lambropoulos S, et al. Treatment of non-small cell lung cancer with gefitinib (‘Iressa’, ZD1839): the Greek experience with a compassionate-use program. Anticancer Drugs2005 ; 16 : 191 –8.

5. Schutte W, Nagel S, Schaedlich S, Brust D, Blankenburg T. Clinical benefit in NSCLC: advanced-stage patients require symptom-improving palliation. Experiences from the ‘Iressa’ expanded access program. Onkologie2005 ; 28 : 195 –8.

Cited by 222 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Gefitinib-Induced Severe Dermatological Adverse Reactions: A Case Report and Pharmacogenetic Profile;Pharmaceuticals;2024-08-07

2. Genetic Variants in the ABCB1 and ABCG2 Gene Drug Transporters Involved in Gefitinib-Associated Adverse Reaction: A Systematic Review and Meta-Analysis;Genes;2024-05-07

3. Effect of genetic polymorphisms on the pharmacokinetics of gefitinib in healthy Chinese volunteers;Xenobiotica;2023-12-12

4. Placental BCRP transporter reduces cadmium accumulation and toxicity in immortalized human trophoblasts;Reproductive Toxicology;2023-10

5. Study on the hepatotoxicity and potential mechanism of gefitinib based on CYP450 in mice and AML12 cells;Journal of Pharmacy and Pharmacology;2023-01-19